
10/04/2025
During the Octane OC Neuro Tech Forum, our CEO, Richard Foust, was featured on the Converging and Emerging Markets for Neurotechnology panel and highlighted 3️⃣ insights gleaned from Vivistim's commercialization journey.
1️⃣ Neurotechnology is expanding workflow, diagnostic and treatment paradigms for patients through bioelectric medicine, AI and brain-computer interface (BCI).
2️⃣ We have to evolve the care pathway for neuro-disease identification and treatment.
3️⃣ The convergence of emerging technology will be the key driver for innovation.
Moderated by Bill Patterson, Ph.D., (VP of Innovation & Technology, Medtronic), the panel also included Ariane Tom, PhD (Founder & Managing Director, Kaleida Capital), and Daniel Levangie (President & CEO, CereVasc).